WHAT IS CLAIMED IS:

biomolecular pharmaceuticals, carrier of 1. comprising:

5

a biomolecule carrier bearing molecules that bind to a cellular adhesion molecule expressed on endothelial cell; and a pharmaceutical.

The biomolecular carrier of claim 1, wherein said 2. molecules that bind to a cellular adhesion molecule is selected from the group consisting of antibodies, antibody fragments and ligands that bind to said cellular adhesion molecule.

15

The biomolecular carrier of claim 1, wherein said 3. carrier is made from a substance selected from the group consisting of biodegradable particles, liposomes, microbubbles, polymersomes, and synthetic secretory granules.

20

4. The biomolecular carrier of claim 1, wherein said cellular adhesion molecule is selected from the group consisting of ICAM-1, E-selectin, P-selectin, VCAM-1, and PECAM-1.

5

5. The biomolecular carrier of claim 1, wherein said pharmaceutical is an anti-neoplastic compound.

6. A method of treating a pathophysiological state in an individual in need of such treatment, comprising the steps of:

irradiating a target tissue or organ in said individual; and administering to said individual the biomolecular carrier of claim 1.

15

7. The method of claim 6, wherein said pathophysiological state is selected from the group consisting of cancer, arteriovenous malformations (AVM), macular degeneration and restenosis.

20